SPARC-deficient mice have a normal hematopoietic recovery following 5-FU treatment. (A) No significant differences in total BM cellularity (arms, legs, hips, and spine) are observed between WT and Sparc^−/− mice following 5-FU treatment (N = 12 per group and time point; mean and standard deviation [SD]; unpaired 2-tailed Student t test). (B) In the BM, there are no significant differences in absolute numbers of Gr1⁺/CD11b⁺ myeloid cells between WT and Sparc^−/− mice at homeostasis and after 5-FU treatment (N = 12 per group and time point; mean and SD; unpaired 2-tailed Student t test). (C-D) Sparc^−/− mice have significantly less (C) HSCs (Lin⁻Sca-1⁺ CD48⁻CD150⁺ CD34⁻) and (D) SLAM HSCs (Lin⁻Sca-1⁺CD48⁻CD150⁺) 11 days after 5-FU (N = 12 per group and time point; mean and SD; ***P < .005; ****P < .001; unpaired Student 2-tailed t test). (E-F) Absolute numbers of LSK and LS⁻K (E) and HSCs (F; Lin⁻Sca-1⁺c-Kit⁺CD48⁻CD150⁺CD34⁻) in WT and Sparc^−/− mice 11 days after 5-FU injection (N = 12 per group and time point; mean and SD; **P < .01; unpaired 2-tailed Student t test).